MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Arcus Biosciences Inc

Geschlossen

BrancheGesundheitswesen

15.04 7.74

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.15

Max

15.15

Schlüsselkennzahlen

By Trading Economics

Verkäufe

132M

160M

Angestellte

627

EBITDA

126M

4M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+119.61% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

566M

1.5B

Vorheriger Eröffnungskurs

7.3

Vorheriger Schlusskurs

15.04

Nachrichtenstimmung

By Acuity

45%

55%

178 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

Arcus Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Okt. 2025, 16:58 UTC

Ergebnisse

BMW Trims 2025 View, Citing Weaker Performance in China

7. Okt. 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7. Okt. 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7. Okt. 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7. Okt. 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7. Okt. 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7. Okt. 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Okt. 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Okt. 2025, 20:44 UTC

Heiße Aktien

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7. Okt. 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7. Okt. 2025, 19:23 UTC

Akquisitionen, Fusionen, Übernahmen

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7. Okt. 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7. Okt. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7. Okt. 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7. Okt. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Okt. 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7. Okt. 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7. Okt. 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7. Okt. 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7. Okt. 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. Okt. 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7. Okt. 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7. Okt. 2025, 14:52 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Arcus Biosciences Inc Prognose

Kursziel

By TipRanks

119.61% Vorteil

12-Monats-Prognose

Durchschnitt 31.8 USD  119.61%

Hoch 52 USD

Tief 14 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arcus Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

9

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

8.01 / 8.75Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Neutral Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

178 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat